Eppendorf Innovation Company (EpIC)

Overview

Eppendorf Innovation Company (EpIC) is the strategic investment arm of Eppendorf SE, focusing on innovative startups in the life sciences sector. EpIC aims to identify and develop new business opportunities to strengthen Eppendorf's innovation leadership. By investing in early-stage companies, EpIC seeks to enhance Eppendorf's portfolio with cutting-edge technologies and solutions. EpIC's investment strategy targets startups in various stages, from seed to pre-IPO, across multiple sectors within the life sciences industry. The company has a global geographical focus, with investments in countries such as Germany, the United States, the United Kingdom, Belgium, South Africa, China, India, Japan, South Korea, Singapore, Australia, Brazil, Canada, France, Italy, Spain, the Netherlands, Sweden, Denmark, and Norway. This broad reach enables EpIC to access a diverse range of innovative companies and technologies. In February 2024, EpIC expanded its international network by investing in Osage University Partners (OUP), a U.S.-based fund specializing in university spinouts. This partnership provides EpIC with access to over 100 startups from U.S. universities, enhancing its ability to identify disruptive and highly innovative research tools and diagnostics companies for potential investments and collaborations. This strategic move aligns with EpIC's mission to strengthen Eppendorf's competitive advantage through early engagement with groundbreaking innovations. EpIC's investment philosophy emphasizes collaboration with startups that align with Eppendorf's core competencies in research tools, diagnostics, and laboratory equipment. By fostering these partnerships, EpIC aims to accelerate the development and commercialization of innovative solutions that address the evolving needs of the life sciences industry, thereby contributing to the advancement of scientific research and improving human living conditions.